Your single destination for free CMEs, medical news, & more. Be Part of the Knowledge.
Joined September 2008
- Tweets 15,963
- Following 2,754
- Followers 2,823
- Likes 3,975
9,359 Photos and videos
Join a leading Spanish expert for a live, interactive webinar series exploring how perioperative immunotherapy may shape evolving treatment strategies in resectable, locally advanced HNSCC. He'll cover patient selection, sequencing approaches, multidisciplinary care integration, and more. Register now: ow.ly/2XvR50Zb7Yb
#HNSCC #Immunotherapy #Oncology #MedEd
5
How should adjuvant therapy be optimized for patients with HER2-positive early breast cancer who remain at high risk after neoadjuvant treatment? The phase 3 DESTINY-Breast05 trial compared T-DXd with T-DM1 and helped inform updated NCCN guidance.
Explore the data in this video brief from ASCO 2026: ow.ly/5S0Z50ZabLN #ASCO2026 #Oncology #BreastCancer
41
How should treatment plans evolve for patients with HER2-positive early breast cancer who remain at high risk of recurrence after neoadjuvant therapy? Explore findings from the phase 3 DESTINY-Breast05 trial comparing T-DXd vs T-DM1 in patients with residual invasive disease: ow.ly/CXzt50Z9G3g #Oncology
36
In case you missed it: a live event exploring treatment options for early symptomatic Alzheimer’s disease. Learn about streamlined referral thresholds, eligibility triage, and amyloid confirmation strategies. This Worldwide Webinar Series has subtitles available in French, German, Spanish, and Portuguese. Wherever you're located, there's a broadcast available. Register now: ow.ly/jh8N50Z4pUs #Alzheimers #MedicalEducation #LiveEvent
21
How might emerging therapies fit into FSGS management? Patients with persistent proteinuria may benefit from alternatives to standard RAS blockade, particularly when long-term tolerability is a priority.
Learn more: ow.ly/hQBS50YFHtN
#FSGS #Nephrology #PatientCare #KidneyHealth
21
Tomorrow: Join Dr. Christophe Le Tourneau live as he examines perioperative immunotherapy strategies in resectable LA HNSCC through clinical evidence and case discussions.
Register now: ow.ly/icH450Z6q5S
#HNSCC #OncologyEducation #Immunotherapy
1
24
Which patients may benefit most from emerging FSGS therapies?
Those with persistent or nephrotic-range proteinuria remain at highest risk and may see meaningful reductions in proteinuria. Explore the clinical considerations: ow.ly/QB3a50Z6GEn
#Nephrology #FSGS
35
Join a leading French expert for an interactive webinar series examining how perioperative immunotherapy may influence treatment paradigms, patient selection, sequencing strategies, and care pathway integration in LA HNSCC. Register: ow.ly/2Pya50Z6pTI
#HNSCC #Immunotherapy #Oncology #MedEd
44
Tomorrow: Get expert insights on early symptomatic Alzheimer’s disease, from evaluation to shared decision-making and care coordination. This worldwide webinar has subtitles available in French, Spanish, German, and Portuguese. Don’t miss it! Register now: ow.ly/2N6w50Z1M8j #Alzheimers #CME
23
Happening tomorrow: a live ASCO symposium on biomarker-informed treatment strategies in ovarian cancer. Engage with real-world cases and clinical insights. Join here: ow.ly/vHtU50Z3qfs
#Oncology #CME
1
31
#Proteinuria is central to #FSGS.
In this video, Dr. Howard Trachtman explains how it signals podocyte dysfunction and filtration barrier disruption in this brief video: ow.ly/Ov3U50XXkIs
1
33
Happening soon: a live program on closing clinical gaps in early symptomatic Alzheimer’s disease, including therapy initiation and monitoring strategies. Subtitles available in French, Spanish, German, and Portuguese. Save your spot: ow.ly/ZfNF50Z1M1q #AlzheimersCare #LiveBroadcast #Neurology
1
21
One week to go. Participate in a live, interactive ovarian cancer symposium featuring quiz polling and expert discussion on biomarker-guided strategies. Save your spot: ow.ly/FuFP50Z3q8h
#ASCO2026 #MedEd
81
What does proteinuria reduction really tell us in FSGS?
Ongoing research efforts are examining how treatment response correlates with long-term kidney outcomes. Hear more about these developments: ow.ly/IWP650YFHim
#KidneyDisease #FSGS #Nephrology #MedicalEducation
38
#Proteinuria reduction plays a central role in FSGS drug evaluation.
With collaborative efforts like the PARASOL initiative, researchers are working to better understand how these changes relate to long-term outcomes. Learn more: ow.ly/owuW50Z1zNC
#FSGS #Nephrology
47
In #FSGS, identifying patients early matters.
Dr. Howard Trachtman explains that proteinuria is the key driver and defining sign of disease, reflecting podocyte dysfunction and disruption of the glomerular filtration barrier: ow.ly/G8GI50YZ29w
1
50
Ahead of #IgANAwarenessDay, see how shared decision-making comes to life in IgA nephropathy care, with real-world insights on proteinuria, GFR, and individualized management strategies.
Dive into an expert-led program: reachmd.com/u/18859
#Nephrology #IgAN #KidneyHealth #MedicalEducation
73
Early symptomatic Alzheimer’s disease presents critical decision points in care. Join a live discussion on referral pathways, diagnostic strategies, and coordinated workflows. This is a worldwide webinar series with subtitles available in French, Spanish, German, and Portuguese! Register here: ow.ly/92Ch50YWEf0 #AlzheimersDisease #CME #Neurology
24
Join a live satellite symposium at ASCO 2026 focused on applying biomarker-driven evidence in ovarian cancer care. Explore case-based decision-making across treatment settings. Register here: ow.ly/pZKh50YWC02
#OvarianCancer #OncologyEducation
1
46
Treating FSGS in younger patients presents unique challenges.
Adverse events and poor tolerability can complicate management decisions. Explore how clinicians are approaching this: ow.ly/SOac50YFH8b
#FSGS #Nephrology #PatientCare #MedicalEducation
33